Smith & Nephew SNATS (SNN) to Release Quarterly Earnings on Tuesday

Smith & Nephew SNATS (NYSE:SNN) is expected to be releasing its Q4 2025 results before the market opens on Tuesday, March 3rd. Analysts expect Smith & Nephew SNATS to post earnings of $1.17 per share and revenue of $1.6754 billion for the quarter. Interested persons can check the company’s upcoming Q4 2025 earning summary page for the latest details on the call scheduled for Monday, March 2, 2026 at 3:30 AM ET.

Smith & Nephew SNATS Price Performance

NYSE SNN opened at $36.94 on Monday. The company has a quick ratio of 1.40, a current ratio of 3.00 and a debt-to-equity ratio of 0.60. Smith & Nephew SNATS has a one year low of $23.91 and a one year high of $38.79. The company has a 50-day simple moving average of $34.16 and a 200-day simple moving average of $34.94.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of the business. Goldman Sachs Group Inc. boosted its holdings in shares of Smith & Nephew SNATS by 5.2% during the fourth quarter. Goldman Sachs Group Inc. now owns 2,053,726 shares of the medical equipment provider’s stock worth $67,383,000 after purchasing an additional 100,697 shares during the last quarter. Bank of America Corp DE grew its holdings in Smith & Nephew SNATS by 139.9% in the 3rd quarter. Bank of America Corp DE now owns 987,274 shares of the medical equipment provider’s stock valued at $35,828,000 after buying an additional 575,666 shares during the period. BNP Paribas Financial Markets increased its stake in shares of Smith & Nephew SNATS by 45.5% during the 3rd quarter. BNP Paribas Financial Markets now owns 937,943 shares of the medical equipment provider’s stock valued at $34,038,000 after acquiring an additional 293,418 shares during the last quarter. Dimensional Fund Advisors LP lifted its holdings in shares of Smith & Nephew SNATS by 48.1% during the 4th quarter. Dimensional Fund Advisors LP now owns 728,667 shares of the medical equipment provider’s stock worth $23,932,000 after acquiring an additional 236,642 shares during the period. Finally, Wells Fargo & Company MN lifted its holdings in shares of Smith & Nephew SNATS by 3.9% during the 4th quarter. Wells Fargo & Company MN now owns 470,471 shares of the medical equipment provider’s stock worth $15,436,000 after acquiring an additional 17,854 shares during the period. 25.64% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of brokerages have commented on SNN. Kepler Capital Markets upgraded Smith & Nephew SNATS to a “strong-buy” rating in a research note on Monday, November 17th. Royal Bank Of Canada downgraded Smith & Nephew SNATS from an “outperform” rating to a “sector perform” rating in a report on Monday, December 15th. Wall Street Zen downgraded Smith & Nephew SNATS from a “strong-buy” rating to a “buy” rating in a research note on Saturday, February 21st. Weiss Ratings reaffirmed a “hold (c+)” rating on shares of Smith & Nephew SNATS in a research report on Wednesday, January 21st. Finally, Canaccord Genuity Group reduced their price target on shares of Smith & Nephew SNATS from $36.00 to $34.00 and set a “hold” rating for the company in a report on Tuesday, November 11th. One equities research analyst has rated the stock with a Strong Buy rating and five have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, Smith & Nephew SNATS presently has an average rating of “Hold” and an average price target of $35.75.

About Smith & Nephew SNATS

Smith & Nephew plc is a global medical technology company specializing in the design, development and manufacture of advanced surgical devices, orthopaedic reconstruction implants, trauma and extremities products, sports medicine solutions and wound care therapies. Founded in 1856 in Hull, United Kingdom, the company has grown through both organic innovation and strategic acquisitions to offer a broad portfolio that addresses patient needs across joint replacement, minimally invasive surgery and wound healing.

In its orthopaedics business, Smith & Nephew provides hip and knee replacement systems, modular joint revision implants and biologic solutions for bone repair.